Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Tao-Hung Ou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gram-Positive Bacterial Infections, Vancomycin-Resistant Enterococci, Bacteremia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Science and Technology Council, Taiwan, Ministry of Health and Welfare, Taiwan, National Taiwan University Hospital.
Abstract (Originalsprache)
Objectives
The aim of this study is to evaluate the benefit of early appropriate antibiotics in vancomycin-resistant Enterococcus (VRE) bloodstream infections (BSIs) amid increasing incidence and limited evidence supporting empirical VRE-active therapy.
Methods
We performed a cohort study (2010–23) involving patients with VRE BSI who received empiric Gram-positive coverage. Patients who did not receive VRE-active therapy (daptomycin or linezolid) were excluded. Based on their initial regimen, patients were classified into an empiric anti-VRE group or a glycopeptide (vancomycin or teicoplanin) group. The primary outcome was 28-day mortality.
Results
We included 134 patients: 46 in the empiric anti-VRE group and 88 in the glycopeptide group. The 28-day mortality rate was 53.7%. All glycopeptide recipients switched to daptomycin, and 29 of the 46 (63%) patients in the empiric anti-VRE group also received daptomycin. Time to VRE-active therapy was shorter in the empiric anti-VRE group (0 versus 2 days; P < 0.001), and each day’s delay correlated with higher mortality (0 day: 37.0%, 1 day: 57.7%, ≥2 days: 64.5%; P = 0.02). The empiric anti-VRE group had a lower 28-day mortality rate (37.0% versus 62.5%, P = 0.006). Multivariable analysis adjusting for comorbidities, steroid use, infection focus and bacteraemia severity indicated that empiric anti-VRE therapy was independently associated with lower mortality (adjusted OR 0.41; 95% CI, 0.17–0.98; P = 0.046).
Conclusions
Among patients with VRE BSI requiring empiric Gram-positive coverage, anti-VRE therapy was associated with reduced 28-day mortality compared with glycopeptides, even both groups eventually received VRE-active antibiotics. This highlights the critical role of timely, appropriate antibiotic to improve VRE BSI outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.
ORCID-Profile: Yee-Chun Chen, Shan-Chwen Chang
Förderung
- National Science and Technology Council, Taiwan
- Ministry of Health and Welfare, Taiwan
- National Taiwan University Hospital
Zitieren
APA
Ou, T. H., Yang, J. L., Lin, C. Y., Huang, S. H., Chuang, Y. C., Wang, J. T., Chen, Y. C., & Chang, S. C. (2025). Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf225
Vancouver
Ou TH, Yang JL, Lin CY, Huang SH, Chuang YC, Wang JT, et al. Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf225
BibTeX
@article{Ou2025,
author = {Ou, Tao-Hung and Yang, Jia-Ling and Lin, Chi-Ying and Huang, Sung-Hsi and Chuang, Yu-Chung and Wang, Jann-Tay and Chen, Yee-Chun and Chang, Shan-Chwen},
title = {Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf225}
}
EUVIMED